Jerini focuses on the discovery, development, and commercialization of novel peptide-based drugs. The company selectively pursues disease indications for which patients have limited or no treatment options.
Jerini Ophthalmic, Inc. is a wholly-owned, independent US subsidiary of the German company, Jerini, AG (FSE:JI4). The Company began operations in March 2007 to focus on the rapid development of novel, extended-release therapeutics for unmet medical needs in ophthalmology. Using Jerini AG's Peptides-to-Drugs (P2D) technology platform, Jerini Ophthalmic is now responsible for developing compounds targeting pathways believed to be involved in several sight-threatening ophthalmic indications.
HAE-Network contributes to the integration and cooperation of anyone affected by the rare disease hereditary angioedema (HAE). The network intends to focus on patients, physicians, scientists, relatives, carers and the public.
Countries outside the U.S. often have regulatory requirements or medical practices that differ from those in the U.S. and sites targeted at residents of those countries may have different or additional information than sites targeted at U.S. residents. Therefore, the information contained in the sites you are about to enter may not be appropriate for use within the United States.